SCI Engineered Materials, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SCI Engineered Materials, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $13.45M | Feb 4, 2022 |
| FY2021 | Dec 31, 2020 | $10.90M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $12.95M | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $11.36M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $6.80M | Feb 5, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $7.98M | Mar 4, 2014 |
| FY2012 | Dec 31, 2012 | $8.76M | Mar 19, 2013 |
| FY2011 | Dec 31, 2011 | $9.15M | Apr 13, 2012 |
| FY2011 | Dec 31, 2010 | $8.92M | Apr 13, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.03M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.07M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.25M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.79M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $3.53M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.20M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $2.21M | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.90M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $1.58M | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $1.08M | Feb 1, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.75M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.86M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.19M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.96M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $1.68M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $1.50M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $305.4K | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $907.9K | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $6.1K | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | ($706.1K) | Feb 1, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.04M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.49M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.48M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $1.78M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $516.3K | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $330.9K | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $934.9K | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $49.1K | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | ($661.0K) | Feb 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $434.4K | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $564.6K | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $501.9K | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $375.7K | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $235.7K | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $337.8K | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $366.5K | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $352.0K | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $330.8K | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $319.5K | Feb 1, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.37M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $2.28M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.40M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $2.61M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $991.0K | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $532.2K | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.65M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $616.0K | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $160.6K | Feb 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $499.8K | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $453.7K | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $536.3K | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $706.2K | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $78.9K | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $380.6K | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $380.9K | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $104.0K | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $89.6K | Feb 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.27M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $15.53M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $17.49M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $11.83M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $9.61M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $8.05M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $7.51M | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $7.65M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $3.95M | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $3.63M | Feb 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.09M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.65M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $6.51M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.08M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $2.87M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.50M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $3.56M | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | $4.12M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | $1.47M | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | $1.35M | Feb 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.18M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $12.89M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $10.98M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $8.75M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $6.74M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $5.55M | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $3.95M | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $3.52M | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $2.48M | Feb 5, 2020 |
| FY2018 | Dec 31, 2016 | $2.27M | Feb 5, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | ($54.3K) | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | ($1.92M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($4.10M) | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | ($6.06M) | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | ($7.74M) | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | ($9.24M) | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | ($9.55M) | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | ($10.46M) | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | ($10.46M) | Feb 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.94M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.75M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.67M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.95M | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $2.92M | Jan 29, 2021 |
| FY2020 | Dec 31, 2019 | $1.83M | Jan 29, 2021 |
| FY2020 | Dec 31, 2018 | $1.80M | Jan 29, 2021 |
| FY2019 | Dec 31, 2017 | $920.8K | Feb 5, 2020 |
| FY2018 | Dec 31, 2016 | $730.4K | Feb 5, 2019 |
| FY2017 | Dec 31, 2015 | $997.2K | Feb 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 1, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 1, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 4.57M | Feb 14, 2025 |
| FY2024 | Dec 31, 2023 | 4.53M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 4.52M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 4.51M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | 4.47M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | 4.37M | Jan 29, 2021 |
| FY2019 | Dec 31, 2018 | 4.28M | Feb 5, 2020 |
| FY2018 | Dec 31, 2017 | 4.19M | Feb 5, 2019 |
| FY2017 | Dec 31, 2016 | 4.09M | Feb 1, 2018 |
| FY2016 | Dec 31, 2015 | 4.02M | Feb 27, 2017 |